C2I Alumin, Frequency Therapeutics, Announces Positive Phase 1/2 Data for Drug Candidate for Hearing
We would like to extend our congratulations to our alumni, Frequency Therapeutics, upon their announcement of positive results from a Phase 1/2 safety trial to evaluate FX-322. FX-322 is an investigational drug candidate designed to facilitate hearing restoration.
If successful, Frequency Therapeutic's lead development program would represent the first time that hearing could be restored in humans with a therapeutic. Their work is "defining a new mode of regenerative medicine: activating progenitor cells within your body to repair damaged tissue."
To read the full article: